MedTrace Logo

Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

NCT01063309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2021-07-28

No results posted yet for this study

Summary

Background:

* Atherosclerosis, the arterial plaques or blockages that cause heart disease, develops in many people by the time they are in their mid-20s. The rate of atherosclerosis in patients with immune system disorders has not been well studied, but it may be very different from the general population.
* Patients with chronic granulomatous disease (CGD) produce less of a group of molecules known as free radicals, which help to fight infection and may play a role in the development of atherosclerosis. Patients with CGD may develop atherosclerosis much more slowly than people without CGD. On the other hand, carrier mothers of children with genetically-linked CGD often have problems with autoimmune problems in addition to a problem with making free radicals. Patients with other immune system disorders also have very different responses to infection, and many of them also have autoimmune-like problems that may change the risk of developing atherosclerosis.

Objectives:

\- To study the prevalence of atherosclerosis in patients with immune system disorders, compared with healthy individuals.

Eligibility:

\- Individuals at least 18 years of age who either have been diagnosed with an immune system disorder or are healthy volunteers.

Design:

* The active part of the study involves one or two visits to the National Institutes of Health Clinical Center for a series of imaging tests and scans.
* Participants will have the following tests during the active part of the study:
* (1) CAT scan to obtain images of the chest arteries and measure the amount of calcium in the artery walls.
* (2) Magnetic resonance imaging scan to obtain images of the coronary and carotid arteries in the chest and neck.
* (3) Electrocardiogram to provide data on current heart function.
* (4) Blood samples to provide data on heart, kidney, and immune system function.
* Participants will be contacted every 2 years in the future for up to 30 years to determine whether they have developed heart disease. Researchers will ask participants to provide contact information for two other people who may likely know how to get in touch with the participant in the future.

Conditions

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • John I Gallin, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-05
Primary Completion
2018-12-31
Completion
2020-08-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01063309 on ClinicalTrials.gov